Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial comparing standard chemotherapy with a newer combination of chemotherapy for people with small cell lung cancer (LU21)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial compared a new combination of chemotherapy called ICE-V (or VICE) with standard chemotherapy for people with small cell lung cancer.
Doctors often treat small cell lung cancer with chemotherapy. When this trial was done, other trials had shown that ICE-V could be a useful treatment for small cell lung cancer. ICE-V is vincristine, ifosfamide, carboplatin and etoposide. In this trial doctors compared ICE-V with
The aims of the trial were to find out
- How well ICE-V worked for small cell lung cancer
- More about side effects and quality of life
Summary of results
The researchers found that ICE-V was a useful treatment for people with small cell lung cancer.
The trial recruited 402 people
- Half had standard chemotherapy
- Half had ICE-V
The researchers analysed the results in 2005. They found that more people lived for longer than 2 years after treatment with ICE-V (20%) than with standard treatment (11%).
The side effects were quite similar in both treatment groups. More people who had standard chemotherapy had a sore mouth. People who had ICE-V were more likely to have numbness (
The researchers also looked at quality of life. People in each treatment group reported a similar quality of life.
When this trial started, about three quarters of the people having standard chemotherapy had a combination of doxorubicin, cyclophosphamide and etoposide. Chemotherapy for small cell lung cancer now usually includes a
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Nick Thatcher
Medical Research Council (MRC)
National Institute for Health Research Cancer Research Network (NCRN)